Danielle Russo, MD
Family Medicine · Nappanee, INNPI 1346249364
Payments from drug & device makers
Across 196 payments — averaging $16.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$443
- AstraZeneca$331
- Novo Nordisk$304
- GSK$280
- Pfizer$257
- Lilly USA, LLC$195
- plus $1K from 32 others
What the payments were for
- Food & beverage$3,13196%
- Other$1254%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 24 | $443 |
| AstraZeneca | 22 | $331 |
| Novo Nordisk | 19 | $304 |
| GSK | 19 | $280 |
| Pfizer | 17 | $257 |
| Lilly USA, LLC | 12 | $195 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $144 |
| Johnson & Johnson | 9 | $128 |
| Welch Allyn | 1 | $125 |
| Amgen | 8 | $122 |
| Astellas Pharma US Inc | 5 | $115 |
| Boehringer Ingelheim | 6 | $86 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 5 | $85 |
| Bayer | 4 | $70 |
| Merck | 4 | $56 |
| Exact Sciences | 3 | $52 |
| Novartis | 3 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Lundbeck LLC | 2 | $34 |
| Eisai Inc. | 2 | $28 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Edwards Lifesciences | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Insulet Corporation | 2 | $24 |
| Corium, LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $16 |
| Abbott | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Phathom Pharmaceuticals, Inc. | 1 | $15 |
| Neos Therapeutics, LP | 1 | $15 |
| Genentech USA, Inc. | 1 | $15 |
| Dexcom, Inc. | 1 | $15 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Dermira, Inc. | 1 | $12 |
| Philips North America LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NONE$125
How this compares
$3,255 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 34 | $44,332 |
| OzempicSemaglutide | 31 | $39,423 |
| MounjaroTirzepatide | 30 | $32,966 |
| FarxigaDapagliflozin Propanediol | 33 | $31,749 |
| TrulicityDulaglutide | 18 | $25,835 |
| EliquisApixaban | 23 | $24,943 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $14,718 |
| XareltoRivaroxaban | 13 | $10,239 |
| LinzessLinaclotide | 13 | $7,108 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 20 | $5,967 |
| GemtesaVibegron | 11 | $5,398 |
| Levothyroxine Sodium | 309 | $2,745 |
| SynthroidLevothyroxine Sodium | 36 | $2,329 |
| Atorvastatin Calcium | 234 | $1,853 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $1,754 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $195 | $58,80148 claims |
| Boehringer IngelheimJardiance | $86 | $44,33234 claims |
| Novo NordiskOzempic | $304 | $39,42331 claims |
| AstraZenecaFarxiga | $331 | $31,74933 claims |
| PfizerEliquis | $257 | $24,94323 claims |
| GSKTrelegy Ellipta | $280 | $14,71817 claims |
| Johnson & JohnsonXarelto | $128 | $10,23913 claims |
| AbbVieLinzess, Synthroid | $443 | $9,43749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Nappanee
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
- Steven SmithIndianapolis$2.5M
- Renee Michelle GalenNewburgh$2.1M
- Eric HewittAvon$1.7M
- Alexander Dela LlanaEvansville$1.6M
- Jonathan ConditMuncie$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.